



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/474,435	12/28/1999	Yongwei Cao	16517.044/15473B	2233

28381 7590 05/01/2006

ARNOLD & PORTER LLP  
ATTN: IP DOCKETING DEPT.  
555 TWELFTH STREET, N.W.  
WASHINGTON, DC 20004-1206

EXAMINER

SALMON, KATHERINE D

ART UNIT PAPER NUMBER

1634

DATE MAILED: 05/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/474,435

Applicant(s)

CAO ET AL.

Examiner

Katherine Salmon

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 28 December 1999.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-57 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## DETAILED ACTION

### *Election/Restrictions*

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:  
Please Note Groups I-IV are subject to further restriction see Section 8.
  - I. Claims 1-17, 19-21, and 24-52, drawn to a first nucleic acid molecule, a second nucleic acid molecule, a transformed cell comprising a promoter region, a collection of non-identical oligonucleotides, and a primer pair, classified in class 536, subclass 23.1, class 435, subclass 419, class 435, subclass 287.2, and class 536, subclass 24.3, respectively.
  - II. Claim 18, drawn to a polypeptide, classified in class 530, subclass 300.
  - III. Claims 22-23, drawn to a computer readable medium, classified in class 711, subclass 100.
  - IV. Claims 53-57, drawn to a method for determining gene expression comprising collecting mRNA, producing labeled nucleic acid molecule, and contacting labeled nucleic acid molecule to a collection of nucleic acid molecules, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). The invention groups are patentably distinct because they are drawn to different products having different

Art Unit: 1634

structures and functions. The nucleic acid of Inventions I are composed of deoxyribonucleotides linked by phosphodiester bonds and assumes the form of a double helix. The polypeptide of Invention II is composed of amino acids linked by peptide bonds and can assume complex tertiary structures. The products of these inventions can be used in materially different processes, for example the DNA of Invention I can be used in hybridization assays and the polypeptide of Inventions IV can be used to make a fusion protein with an enzymatic function. Consequently, the reagents, reaction conditions, and reaction parameters required to make or use each group are different. Therefore, the inventions of the groups drawn to nucleic acids, and polypeptides are patentably distinct from each other. The search for each of groups presents a serious search burden, as the searches for each are not coextensive in scope. The inventions have different status in the art as shown by their different classifications. In cases such as this one where descriptive sequence information is provided, the sequences are searched in appropriate databases. There is search burden also in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to polypeptides, which would not have described the polynucleotides. Similarly, there may have been "classical" genetics papers, which had no knowledge of the polypeptide but spoke to the gene. Searching, therefore is not coextensive.

Because nucleic acids and polypeptides are functionally and patentability distinct from each other, the groups associated with each one of these products are patentability distinct from each other and therefore are not related.

Art Unit: 1634

3. Groups I and III are drawn to distinct products. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the groups are drawn to distinct products, Invention I is drawn to nucleic acids and Group III is drawn to a computer medium. The products share a common element wherein they are both drawn to nucleic acids. Beyond this commonality, however, the products are distinct as each product is produced in a different way and each model has a different function. The search for each of groups presents a serious search burden, as the searches for each are not coextensive in scope.

4. Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the nucleic acids of Invention I can be used in a method for determining gene expression or can be used to make antisense nucleic acids for gene therapies. The search for each invention presents a serious burden, as the searches for each are not coextensive in scope. Art relating to the descriptive sequence information on the nucleic acids would not necessarily provide descriptive information on the method for determining gene expression.

Art Unit: 1634

5. Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, Invention II is drawn to a polypeptide whereas Invention III is drawn to a computer readable medium. There is no indication that the polypeptide of Invention II is used with a computer readable medium and therefore there is no relationship between the two inventions.

6. Inventions II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, Invention II is drawn to a polypeptide whereas Invention IV is drawn to a method of detecting gene expression in nucleic acids. There is no indication that the polypeptide of Invention II is used in the method of Invention IV and therefore there is no relationship between the two inventions.

7. Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, Invention III is drawn to a computer readable medium whereas Invention IV is drawn to a method of detecting gene expression in nucleic acids. There is no indication that the computer readable medium of Invention III is used in the method of Invention IV and therefore there is no relationship between the two inventions.

8. Additionally, each group named above is subject to further restriction. Applicant is required to further elect for Group I: a specific sequence for the first purified nucleic acid molecule from SEQ ID Nos. 81307-195836, a specific sequence for the second purified nucleic acid molecule from SEQ ID Nos. 81307-195836, with regard to the transformed cell a specific promoter region for the transformed cell from SEQ ID Nos. 1-81306 and a specific gene sequence from SEQ ID No. 138061-195836, with regard to the collection of nucleic acids the applicant must pick either a specific nucleic acid sequence or a specific combination of nucleic acid sequences from SEQ ID No. 38061-195836, with regard to the primer pair applicants must pick a specific primer pair sequence from SEQ ID No. 138061-195836. For Group II applicant must elect a specific sequence from the group of SEQ ID No. 138061-195836. For Group III, applicant must elect either a specific sequence or a specific combination of sequences from SEQ ID No. 138061-195836. For Group IV applicant must elect a specific sequence or specific combination of sequences from SEQ ID Nos. 138061-195836. These further restrictions are NOT election of species. Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 USC 121 and 37 CFR 1.141. By statute, "[i]f two or more independent and distinct inventions are claimed

in one application, the Commissioner may require the application to be restricted to one of the inventions.” 35 U.S.C. 121. Pursuant to this statute, the rules provide that “[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant... to elect that invention to which his claim shall be restricted.” 37 CFR 1.142 (a). See also 37 CFR 1.141(a). It is noted that searching more than one of the claimed patentably distinct sequences represents a serious burden for the office.

9. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims



Art Unit: 1634

and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

10. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because Inventions I-IV require different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

11. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1634

12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katherine Salmon whose telephone number is (571) 272-3316. The examiner can normally be reached on Monday-Friday 8AM-430PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*Katherine Salmon 4/20/2006*

Katherine Salmon  
Examiner  
Art Unit 1634

*J. Goldberg*  
JEANNE A. GOLDBERG  
4/26/06